About Us

OUR LEADERSHIP

Executive Leadership Team

Pete Salzmann, M.D., MBA

Pete Salzmann, M.D., MBA

Pete Salzmann, M.D., MBA

Chief Executive Officer

Pete Salzmann, M.D., M.B.A, is the Chief Executive Officer of Immunovant and a member of our board of directors. From November 2018 to June 2019, he served as a Global Brand Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and oversaw Phase 2 and 3 clinical trial execution. From March 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.

Renee Barnett, MBA

Renee Barnett, MBA

Renee Barnett, MBA

Chief Financial Officer

With two decades of experience in healthcare, Renee is a passionate and effective leader, who thrives in fast-paced growth organizations. Renee began her career at Eli Lilly where her roles included CFO of Lilly Austria and Switzerland, global lead for Financial Planning and Analysis, and financial lead of a partnership with Amylin Pharmaceuticals. Prior to joining Immunovant, she served in a variety of executive leadership functions, including Finance, Human Resources, Data & Analytics, Call Center Operations, and Technology Transformation at AbleTo, Inc., a leading technology-enabled behavioral health provider. Renee holds an M.B.A. from Harvard Business School and a B.A. in Physics from DePauw University.

Julia G. Butchko, Ph.D.

Julia G. Butchko, Ph.D.

Julia G. Butchko, Ph.D.

Chief Development Officer

Julia joined Immunovant in 2019 as Chief Development and Technology Officer responsible for program and alliance management, clinical operations, biologic/device development, and manufacturing. She helped Immunovant grow from a private, early-phase company to a publicly traded company with multiple global pivotal trials including nonclinical and clinical development of IMVT-1401 and IMVT-1402. Prior to Immunovant, Julia oversaw strategy and operations as Chief of Staff for the $4 billion Immunology and Neuroscience businesses at Eli Lilly and Company. She previously served as Vice President of Lilly’s Oncology Portfolio Management and Clinical Development teams where she was responsible for over 100 global clinical trials including immuno-oncology collaborations with Merck, Bristol-Myers Squibb, and AstraZeneca. Earlier in her career, Julia held significant roles in product development, marketing, manufacturing, and quality.

Julia holds a B.S. in Chemistry from the State University of New York at Fredonia, a Ph.D. in Chemistry from Pennsylvania State University, and a Business Certificate from Indiana University’s Kelley School of Business.

Michael Geffner M.D., MBA

Michael Geffner M.D., MBA

Michael Geffner M.D., MBA

Chief Medical Officer

Prior to joining Immunovant, Dr. Geffner was the Chief Medical Officer and head of Product Development for BlueSphere Bio (BSB), an Immuno-Oncology company focused on developing adoptive T-cell therapeutics. Before his role at BSB, he led Hematology Clinical Development for the danicopan development program and was the Head of Global Medical Affairs for Achillion Pharmaceuticals (now Astra Zeneca). Prior to Achillion, he spent 15 years in various senior leadership positions at Schering-Plough/Merck across Clinical Development, Clinical Operations, and Medical Affairs. His other prior roles include, Head of the Anti-infectives/hospital and specialty care Medical Affairs teams, US Medical Affairs integration lead, and Clinical Development Leader.

Dr. Geffner has dual board certification from the American Board of Pediatrics and The American Board of Psychiatry and Neurology, with special competency in Child Neurology. He is a Graduate of Albany Medical College and holds an MBA from Fairleigh Dickinson University

Julie Kirschling

Julie Kirschling

Julie Kirschling

Senior Vice President, Program and Alliance Management

Prior to joining Immunovant, Julie spent 33 years in a variety of project leadership roles at Eli Lilly & Company. She is an experienced project and functional Leader with a proven track record of developing and leading high performing cross-functional teams to enable business critical outcomes and maximizing performance of others with and without direct authority. She has 30+ years of pharmaceutical development experience and 20+ years of experience leading projects across all phases of development and therapeutic areas including leading successful submissions for two marketed products. 

She holds a B.S. degree in Chemical Engineering from Purdue University and is a certified Project Management Professional.

Mark Levine

Mark Levine

Mark Levine

Chief Legal Officer and Corporate Secretary

Mark has more than 25 years of legal experience, including negotiating mergers, acquisitions, and divestitures; managing licensing agreements and partnerships; and providing counsel to optimize development and commercialization. Mark most recently served as General Counsel and Corporate Secretary of Flexion Therapeutics, Inc., a commercial stage biopharmaceutical company, where he was a member of the executive committee and was responsible for overseeing all legal and compliance affairs related to Flexion’s launch of ZILRETTA® in the United States in 2017 and building its pipeline. Mark’s tenure at Flexion culminated in the acquisition of the company by Pacira BioSciences, Inc. in late 2021. Mark previously served as General Counsel and Corporate Secretary at Minerva Neurosciences, Inc.

Mark holds a B.A. from Binghamton University, SUNY, and a J.D. from Washington University School of Law in St. Louis.

Bill Macias, M.D., Ph.D.

Bill Macias, M.D., Ph.D.

Bill Macias, M.D., Ph.D.

Chief Medical Officer

From 2018 to May 2021, Bill was the Chief Executive Officer at Focus Biomedical Consulting LLC, and in that role was the interim Chief Medical Officer for Promethera Biosciences S.A. from 2019 through 2020. From 1994 through 2017, Bill was at Eli Lilly and Company. At Lilly, he led multiple clinical development programs, leading to the submission and approval of medications across diverse therapeutic areas in both biologic and small molecules. From 2011 onward, he held multiple global development leadership roles in the Biomedicines Business Unit. Prior to joining Eli Lilly and Company, he was an Associate Professor of Medicine at Indiana University School of Medicine.

Bill earned a B.A. in Biology from Marquette University and both an M.D. and Ph.D. from Indiana University School of Medicine. He held board certifications in Internal Medicine, Nephrology, and Critical Care in Medicine.

Jody Roth, MS, RAC, PMP

Jody Roth, MS, RAC, PMP

Jody Roth, MS, RAC, PMP

Senior Vice President, Regulatory Affairs

Jody is recognized for her communication and advocacy of label-in-mind concepts, as well as her expertise in FDA interactions. Prior to joining Immunovant, Jody held leadership positions at Outpost Medicine, Gate Neurosciences, and Guidehouse where she set up new molecules for a successful global registration across multiple regions. Prior to roles in biotech, Jody spent 25 years at Eli Lilly and Company established robust filing experience across the drug development lifecycle where she supported the initiation of new molecules and obtaining US approvals for BLAs and NDAs.

Jody has her B.S. in Animal Science and M.S. in Growth Physiology/Immunology from Purdue University. Jody is a member of Regulatory Affairs Professionals and Project Management Institute.

Jay S. Stout, PhD

Jay S. Stout, PhD

Jay S. Stout, PhD

Chief Technology Officer

Jay is the Chief Technology Officer at Immunovant. From 2020 until April 2023, he was an independent consultant supporting the scale up and validation of late-stage products in immunology and cell and gene therapy. From June 2018 until January 2021, he led the Technical Operations at Immunomedics (Gilead) leading to the approval of an antibody drug conjugate for oncology. Prior to that Jay has held various senior leadership roles in Technical Operation at Versartis (Aravive), San Bio, Merck, Amgen, Pfizer, and BioNebraska (Restoragen). He has a proven track record of Biologic approvals for Monoclonal Antibodies, Antibody Drug Conjugates, and Cell and Gene Therapies.

Jay received a B.S. and M.S. in Chemistry from the University of Iowa and a Ph.D. in Chemistry and Biochemistry from the University of Nebraska-Lincoln. Dr. Stout has served on the Amgen Center for BioProcessing Advisory Board at the Keck Graduate Institute for more than 10 years and was the Chair of the Advisory Board from 2021-2023.

Senior Management

Maria Alba, M.D.

Maria Alba, M.D.

Maria Alba, M.D.

Vice President of Clinical Development

Maria has over 16 years of experience across all phases of development in rare disease, endocrinology, and metabolism. Prior to joining Immunovant, Maria was the Global Medical Leader at Amicus Therapeutics for a phase 2 and 3 clinical program for the development of a second-generation enzyme replacement therapy for Pompe disease. Prior to Amicus Therapeutics, Maria held clinical roles at Vertex, Merck, and Janssen Pharmaceuticals.

Maria earned her M.D. from the Catholic University in Rome, Italy, where she also completed her fellowship in endocrinology and metabolism. Maria went on to complete a post-doctoral fellowship for preclinical research on growth hormone deficiency at the Johns Hopkins University.

Jennifer Ashley

Jennifer Ashley

Jennifer Ashley

Vice President, Associate General Counsel

Jennifer has over 23 years of experience providing legal and business advice for technology and pharmaceutical companies, advising on complex business transaction, product development, and commercialization/compliance matters. She started her career at Cooley LLP, before transitioning to various in-house roles of increasing scope and oversight responsibility. Most recently, Jennifer served as Senior Vice President, Legal for a commercial stage, public biopharma company, overseeing legal support for the in-licensing, development, launch and commercialization of oncology products in multiple indications.

Jennifer holds a B.A. in Biological Sciences and Sociology from Southern Methodist University and a J.D. from The University of Texas School of Law.

Ronald Bates, Ph.D.

Ronald Bates, Ph.D.

Ronald Bates, Ph.D.

Process Development and Technical Operations

Ronald has more than 20 years of experience in the biopharmaceutical industry, holding roles of increasing responsibility in process development, manufacturing science and technology (MSAT), and manufacturing. Prior to joining Immunovant, Ronald was in MSAT at Bristol-Myers Squibb in Syracuse, NY, where he was part of the development and commercialization of numerous protein therapeutics. He has also held roles at Pfizer and Allergan.

Ronald earned a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and a Ph.D. in Biochemical Engineering from the University of Maryland, Baltimore County. Ronald is on the editorial board of the Biotechnology Journal and the advisory group for Albany College of Pharmacy and Health Sciences’ Center for Biopharmaceutical Education and Training.

Christine Blodgett

Christine Blodgett

Christine Blodgett

Vice President of Human Resources

Christine brings 20 years of progressive human resources leadership experience across several industries and growth phases, from startups to the Fortune 100. She's spent the majority of her career focused on the biotechnology and pharmaceutical industries. Most recently, as the head of HR at Turnstone Biologics, Christine oversaw the Company’s talent strategy and management, learning and development programs, and all matters relating to Turnstone’s people and culture. Prior to that, Christine served as HR Director at Honeywell and held multiple leadership roles at Bristol-Myers Squibb and Medarex, Inc.

Christine holds a B.S. in Business Administration from The College of New Jersey and earned two certifications: a Strategic Human Resources Practices certification from Cornell University and a Professional in Human Resources (PHR) certification.

Chau Cheng, Ph.D., M.B.A.

Chau Cheng, Ph.D., M.B.A.

Chau Cheng, Ph.D., M.B.A.

Vice President of Investor Relations

Chau has more than 18 years of experience leading the investor relations function of small- and mid-cap biotech companies. Chau most recently served as Vice President, Investor Relations and Corporate Communications at CytomX Therapeutics. Prior to CytomX, Chau spent more than 16 years at Immunomedics during which the company transformed from a research and development-oriented organization to a fully-integrated biopharmaceutical enterprise.

Chau earned a B.Sc. (First Class Honors) in Chemistry from University of Bradford, the United Kingdom, a Ph.D. in Organic Chemistry from The Open University, the United Kingdom, and a M.B.A. in Finance and International Business from Stern School of Business, New York University.

Andy Deig

Andy Deig

Andy Deig

Vice President, Financial Planning and Chief of Staff to the CEO

Prior to joining Immunovant, Andy spent almost 13 years at Eli Lilly & Company where he held numerous roles in different functions across the business, including finance, sales, and value & access. Most recently, Andy served as the national account manager for McKesson and Walmart after leading the commercial integration of Dermira.
Andy earned a B.A. from Wabash College in 2008 with majors in Economics and German and an M.B.A. in health sector management and strategy from Duke’s Fuqua School of Business in 2016.

Tom Forman

Tom Forman

Tom Forman

Vice President, CMC Project Management

Prior to joining Immunovant, Tom spent over 30 years with Eli Lilly where he had numerous roles across Manufacturing, CMC Development, and Portfolio Leadership.  He brings over 20 years of experience leading CMC teams in all phases of development from pre-clinical to seeing the successful launch of multiple marketed products.  Most recently, he was the early phase portfolio leader for Diabetes and Obesity development.

He holds a BS degree in Chemical Engineering from Purdue University and an MBA with Healthcare focus from the Kelley School of Business at Indiana University.  Tom is a registered Project Management Professional.

Ian Gourley, M.D.

Ian Gourley, M.D.

Ian Gourley, M.D.

Vice President of Clinical Development

Ian is a translational medicine and clinical development physician with over 20 years of experience in the biopharma industry. He has focused on early development of both large and small molecules in the immunology/inflammation space. Prior to joining Immunovant, Ian worked at CSL Behring in Clinical Pharmacology & Translational Development, where he was responsible for strategy and clinical oversight of early development programs in the immunology therapeutic area. Prior to CSL Behring, he held positions as Head of Translational Medicine Science, Immunology, at Janssen and in Clinical Precision Medicine at Pfizer. Ian started his industry career with Eli Lilly as a clinical research pathologist.

Ian received his M.B., B.Ch. and completed his M.D. thesis, both from Queen’s University of Belfast, and is a member of the Royal College of Physicians. He is a board-certified clinical pathologist and is accredited by the American Society for Histocompatibility and Immunogenetics as an HLA laboratory director.

Thomas Hardy, M.D., Ph.D.

Thomas Hardy, M.D., Ph.D.

Thomas Hardy, M.D., Ph.D.

Vice President of Drug Safety and Pharmacovigilance

Tom is a physician scientist with extensive early- and late-phase clinical development expertise. Prior to joining Immunovant, Tom spent 18 years at Eli Lilly and Company, holding key roles in all phases of clinical development. He oversaw numerous IND filings and directed the design and implementation of phase 1 and 2 clinical trials across multiple disease areas. Tom went on to direct multiple global registration trials in the Diabetes Business Unit, resulting in two global approvals. Before joining Lilly, he ran a busy clinical practice in endocrinology.

Tom earned a B.A. in Biology from University of California, Santa Cruz, and he earned his M.D. and Ph.D. in Biochemistry from Indiana University. He completed fellowship training in Diabetes, Endocrinology, and Metabolism at Vanderbilt Medical Center.

Aileen Ilaria, MBA

Aileen Ilaria, MBA

Aileen Ilaria, MBA

Vice President Clinical Operations

Aileen brings an extensive depth of drug development experience in global operations including trial design and execution across a broad array of indications.  Prior to joining Immunovant, Aileen was at HUTCHMED International where she was responsible for portfolio and project management and business operations for the execution of the international portfolio.  While spending almost 20 years at Eli Lilly and Company, Aileen was a collaborative leader with a proven track record of delivering broad transformational initiatives and excelled in a fast-paced, innovative, and dynamic environment.  Before joining Eli Lilly, Aileen worked at several academic medical centers in both clinical and research administration roles.

Aileen holds a B.A in Sociology/Pre-Med from Boston College and an MBA with a concentration in healthcare administration from Boston University.

Claudia Jacobs, Ph.D.

Claudia Jacobs, Ph.D.

Claudia Jacobs, Ph.D.

Vice President of CMC Project Management Operations and Clinical Supply

Prior to joining Immunovant Claudia spent over 15 years at Eli Lilly & Company where she held numerous roles in product development in CMC, Clinical Trial Materials Manufacturing and Operations, Clinical Supply and Quality roles, supporting early and late phase program as well as launching products to market. Most recently Claudia was a consultant for biotechnology start-up companies as CMC Project Manager, CMC Development Lead, and Quality Assurance Head for early phase programs small and large molecules.

Claudia obtained her Pharmacy Degree from the University of Hamburg, Germany and earned her Ph.D. in Pharmaceutical Technology from The Free University of Berlin, Germany.

Jonathan Janes, MB

Jonathan Janes, MB

Jonathan Janes, MB

Vice President Clinical Development

Before joining Immunovant, Jonathan held numerous roles working on diabetes, endocrine, and cardiovascular products at Eli Lilly and Company. Between 2009 and 2021 he held various global Medical Director roles, in critical care, immunology and dermatology. While at Eli Lilly he took a lead medical role in the development of both biologic and small molecules leading to successful product submissions and approvals. 

Jonathan received a First-Class Honours degree from London University in 1983. Qualifying in Medicine in 1988 from the University of Wales, he trained in the University Hospital of Wales, becoming a Member of the Royal College of Physicians in 1992. In 2005 he was made a Fellow of the Royal College of Physicians of Edinburgh, and in 2021 he also became a Fellow of the Faculty of Pharmaceutical Medicine.

Ant Kidwell

Ant Kidwell

Ant Kidwell

Vice President of IT and Facilities

Prior to joining Immunovant, Ant led IT and Facilities at Iterum Therapeutics. He has over 25 years of experience in the pharmaceutical industry, with the last 11 years setting up and leading IT and facilities at Bio-tech start-ups. Ant’s leadership in IT, cybersecurity, and facilities enables true partnership between IT and business functions to further the goal of delivering needed medicines to patients.

He holds a B.Sc. In Information Management from Albertus Magnus College.

Chedvi Levin-Sister

Chedvi Levin-Sister

Chedvi Levin-Sister

Vice President of Finance

Chedvi’s expertise includes regulatory compliance (PCAOB, US GAAP, SEC, and IFRS), technical and income tax accounting, revenue recognition (inclusive of gross-to-net in domestic US pharma), stock-based compensation, and leases. She has deep transactional experience in carve-out and business combinations along with implementation of internal controls over financial reporting, including remediation of material weaknesses. Prior to Immunovant, Chedvi spent over 15 years at PwC, where she held numerous roles, most recently as Assurance Director, serving a range of industries and global clients including large pharmaceutical, life science and medical device companies, SEC registrants, technology, and startup companies.

Chedvi earned a B.A. (cum laude) in Management Accounting and Information System from the Jerusalem College of Technology, Israel. She is a CPA (Is).

Launi Masterson

Launi Masterson

Launi Masterson

Vice President of Clinical Operations

Launi has more than 25 years of drug development experience in the areas of Global Trial Execution, CRO oversight, client relationship management, vendor management and clinical operations. Prior to Immunovant, Launi led execution of clinical trials at Metavant Sciences, in metabolic disorders. Prior to Metavant, Launi led diverse teams in large pharma, biotech, CROs, and as an entrepreneur managing professionals across a diverse scope in clinical trial planning and delivery.

Launi holds a B.S. degree in Environmental and Biological Sciences from Rutgers University, Cook College.

Linda McKerral

Linda McKerral

Linda McKerral

Vice President, CMC Analytical Sciences

Linda joins Immunovant with over 20 years experience in Vaccines and Biologics development and commercialization.  Prior to joining, she held various leadership roles overseeing Analytical, Technical Operations and Quality Control functions during her 6 years at Moderna.  There, she also led various technical development teams, advancing notable infectious disease vaccine and personalized cancer therapy programs.  She scaled analytical development and QC departments to facilitate the company’s rapid growth and evolution. Linda’s career began at Merck and over 15 years she held various technical and leadership roles spanning bioprocess/ analytical development to leading external collaborations.  Prior to departing Merck, she was overseeing a large network of CRO’s for pre-/clinical bioanalysis for large molecules, including complex oncology clinical development programs.

Linda holds a Master of Science degree in Microbiology from the University of Guelph, Canada and a Bachelor of Science degree in Biology from the University of Waterloo, Canada. She is a Certified Project Manager (CPM).  

Paola Mina-Osorio M.D., Ph.D.

Paola Mina-Osorio M.D., Ph.D.

Paola Mina-Osorio M.D., Ph.D.

Vice President of Medical Affairs

Paola is an immunologist focused on autoimmune diseases. Prior to joining Immunovant, she held positions of increasing responsibility at Hoffmann-La Roche, Eli Lilly, Regeneron Pharmaceuticals, and Aurinia Pharmaceuticals. Paola has spent the last 10 years of her industry career in Medical Affairs supporting the launch of several innovative drugs in the immunology space.

Paola obtained her M.D. and Ph.D. from the Central University of Ecuador School of Medicine and the National Autonomous University of Mexico Institute of Biomedical Research. She completed her postdoctoral training at the Center for Vascular Biology, University of Connecticut Health Center, and at the Feinstein Institutes for Medical Research, Northwell Health.

Jennifer Moseley

Jennifer Moseley

Jennifer Moseley

Vice President of Clinical Operations

Jennifer has more than 25 years of drug development experience in the areas of global operations, CRO oversight and management, and operational excellence in clinical trial delivery. Prior to joining Immunovant, Jennifer was at Astellas, where she was responsible for managing program delivery teams supporting regulatory filings, clinical inspection activities, and operational excellence initiatives. Prior to Astellas she spent 16 years at Abbott/AbbVie, where she contributed to development and global submissions for 2 approvals that resulted in new treatment paradigms for AIDS and HCV patients.

Jennifer holds a B.Sc. in Microbiology from the University of Illinois at Urbana-Champaign.

Sheetal Patel M.D., MS MBA

Sheetal Patel M.D., MS MBA

Sheetal Patel M.D., MS MBA

Vice President of Clinical Development

Sheetal is a physician with more than 20 years of experience in academia and the biopharmaceutical industry. She has held key roles in all phases of clinical development, medical affairs, and data generation. She has led cross-functional teams for filing of multiple BLA, NDA and device submissions, bringing multiple products to market. Her skillsets expanse from Phase I-IV, registrations trials, prelaunch, launch and LCM in various therapeutic areas globally. Sheetal has worked across large and small biopharmaceutical companies, including: Baxter, Abbott, Shire, Takeda, Bayer, Exact Sciences, Relmada and Lundbeck. She also held positions at Rush University Medical Center and University of Illinois and other Chicago Hospitals prior to making her transition to industry.

Sheetal received her MD from Medical University of Lublin and a Master of Clinical Research from Rush University. In 2022, Sheetal received her Executive MBA from MIT (Massachusetts Institute of Technology).

Rod Saponjic Ph.D., MBA

Rod Saponjic Ph.D., MBA

Rod Saponjic Ph.D., MBA

Vice President of Clinical Operations

Rod has more than 25 years of drug development leadership experience in the areas of global operations, project management, clinical operations, clinical systems, and vendor management. Prior to Immunovant, Rod led Clinical Operations at Respivant, responsible for the management of Phase 1-3 trials in the areas of immunology and respiratory disease. Prior to Respivant, Rod led global development operations at Greenwich Bioscience, resulting in the NDA submission and the first FDA approval of a cannabinoid therapy. Prior to Greenwich, Rod has held senior management positions at Alkensa, Clingenix, Patara Pharma, PRA International, AirPharma, Quintiles, and Synteract.

Rod earned his B.A. in Psychology at Texas Tech University. He earned his M.S. and Ph.D. in Neuroscience at Texas Christian University and an M.B.A. at Baker University.

Lauren Schrier, MBA

Lauren Schrier, MBA

Lauren Schrier, MBA

Vice President of Marketing

Lauren brings expertise in commercial product strategy and execution in immunology. Prior to joining Immunovant, Lauren held multiple leadership roles at Celgene, including experiences spanning Global Marketing, Commercial Development, Project Leadership, and Chief of Staff for the Inflammation and Immunology franchise. Prior to Celgene, Lauren worked in management consulting at Accenture and Easton Associates, where she advised life science clients in opportunity assessment, strategy, and development engagements.

Lauren earned a B.S.E. in Chemical and Biomolecular Engineering from the University of Pennsylvania, and an M.B.A. in Healthcare and Pharmaceutical Management from Columbia Business School.

Yan Zheng, Ph.D.

Yan Zheng, Ph.D.

Yan Zheng, Ph.D.

Vice President of Biostatistics and Programming

Yan brings more than 16 years of experience with broad knowledge in diverse aspects of drug development, including real-world evidence and medical affairs, microbiome biosciences, and across multiple therapeutic areas. Prior to Immunovant, Yan led biometrics at Kaleido Biosciences, where she built and led the biometrics team and strategic and operational planning of biometric resources and contributions. Prior to Kaleido Biosciences, Yan held roles at Sarepta Therapeutics, Merck, Allergan, and Sanofi.

Yan earned a B.S. in Probability and Statistics from Peking University in China. She has an M.S. and Ph.D. in Biostatistics from the University of Minnesota, Twin Cities.

OUR BOARD OF DIRECTORS